A complete application in a minute — tailored resume and cover letter, ready to send.
CSL Seqirus is seeking a Senior Programmer to own the technical delivery of one or two clinical trials from first line code through submission package. This hands-on role gives real authority to shape data structures, SDTM/ADaM outputs, and reports for regulatory review.
Hybrid base in Maidenhead (3 days on site). You will collaborate with statisticians, data managers, medical writers and regulatory colleagues, setting standards, mentoring programmers, and ensuring submission‑ready datasets and
CSL is looking for a Senior Programmer to take technical ownership of one or two clinical trials from first line of code to final submission package. This is a hands‑on statistical programming role with real authority attached to it: you'll be the person a study team turns to when the data needs to hold up under regulatory scrutiny, and the person who decides how a dataset gets built, not just who builds it. You'll work alongside statisticians, data managers, medical writers and regulatory colleagues as a peer, not a downstream resource - reading protocols and SAPs early enough to shape how a study's analysis gets structured, then seeing that structure through to submission‑ready SDTM and ADaM datasets, TFLs, and supporting documentation.
Hybrid Based (3 days a week onsite) in Maidenhead
Clinical data is only as useful as the programming behind it is trustworthy. Every regulatory decision downstream - every safety signal caught or missed, every submission accepted or queried - traces back to whether the datasets and outputs were built right the first time. This role sits at that pressure point. You're not just executing specifications; you're often the one writing them, catching the ambiguity in a protocol before it becomes a data problem three months later, and making the judgment calls that keep a study's analysis both scientifically sound and audit‑ready.
CSL Seqirus is part of CSL. As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state‑of‑the‑art production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.